Skip to content
AnalystLens

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Nov 10, 2025)

Reports
Regulation FD
Filing Date
Filed November 10, 2025
Period End
November 10, 2025
Security
ELV
In the record · 2016–202610-K1110-Q348-K133

ELV filed 11 annual reports (10-K), 34 quarterly reports (10-Q) and 133 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Aug ’21Aug ’21
  2. Leadership change8-K · Aug ’23Aug ’23

01—Abstract

Summary

Summary of the 8-K filed November 10, 2025. Cited figures are marked; the original filing is the authoritative source.

Elevance Health, Inc. (ELV) has filed an 8-K report on November 10, 2025, primarily to reaffirm its financial guidance for the full year 2025 during upcoming investor meetings.

The company expects to maintain its previously issued earnings per diluted share guidance of approximately $24.70a. This figure notably includes approximately $5.30 per diluted share attributable to net unfavorable items. Excluding these specific items, Elevance Health anticipates adjusted earnings per diluted share to remain at approximately $30.00, consistent with prior expectations and not incorporating any additional adjustments beyond those already reported in the third quarter of 2025.

In addition to earnings guidance, the company also reaffirmed its full-year 2025 benefit expense ratio guidance, projecting it to be around 90.0%b. Management attributes these expectations to their current assessment of market conditions, operational performance, the prevailing regulatory and policy environment, and refined business assumptions, including cost trends and medical claims payable estimates. Investors are reminded that actual results could materially differ from these projections due to potential changes in business factors or underlying assumptions.

02—Key points

Key Highlights

  1. Elevance Health reaffirms full-year 2025 earnings per diluted share guidance of approximately $24.70.
  2. Net unfavorable items are estimated to impact EPS by approximately $5.30 per diluted share for FY2025.
  3. Adjusted earnings per diluted share guidance for FY2025 remains at approximately $30.00.
  4. The company expects the benefit expense ratio for full-year 2025 to be approximately 90.0%.
  5. Guidance reaffirmation is based on current market conditions, operational performance, regulatory landscape, and refined business assumptions.
  6. The report includes forward-looking statements and a cautionary note about potential material differences in actual results.

03—Questions

Frequently Asked Questions

  1. What is the primary purpose of this 8-K filing?

    The primary purpose of this 8-K filing is to inform investors that Elevance Health, Inc. will be reaffirming its financial guidance for the full year 2025 during upcoming meetings with investors.

  2. What is Elevance Health's reaffirmed earnings per share (EPS) guidance for 2025?

    Elevance Health reaffirms its guidance for full-year 2025 earnings per diluted share to be approximately $24.70. This includes an estimated $5.30 per diluted share from net unfavorable items, leading to an adjusted EPS expectation of approximately $30.00.

  3. What is the expected benefit expense ratio for 2025?

    The company expects its benefit expense ratio for the full year 2025 to be approximately 90.0%.

  4. What factors are influencing the company's current guidance?

    The reaffirmed guidance reflects management's current view of market conditions, operational performance, the regulatory and policy landscape, and refinements in key business assumptions, such as cost trends and medical claims payable estimates.

04—Continue

← View all 8-K filings